Page last updated: 2024-08-23

selegiline and Movement Disorders

selegiline has been researched along with Movement Disorders in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19909 (60.00)18.7374
1990's4 (26.67)18.2507
2000's1 (6.67)29.6817
2010's1 (6.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Doyu, M; Ibi, T; Niwa, J; Taguchi, S1
Bertoni, JM; Hauser, RA; Molho, E; Sethi, KD; Waters, CH1
Birkmayer, W; Knoll, J; Riederer, P; Youdim, MB1
Barthalmus, GT; Hardin, LK; Thompson, D1
Burns, RS; Davis, TL; Roznoski, M1
Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ1
Durif, F1
Lander, CM; Lees, A; Stern, G1
Antal, J; Antóny, M; Csanaky, A; Csanda, E1
Rinne, UK; Siirtola, T; Sonninen, V1
Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F1
Csanda, E; Takáts, A; Tárczy, M1
Dubuis, R1
Fornadi, F; Ulm, G1
Mihatsch, W; Przuntek, H; Russ, H1

Reviews

2 review(s) available for selegiline and Movement Disorders

ArticleYear
Treating and preventing levodopa-induced dyskinesias: current and future strategies.
    Drugs & aging, 1999, Volume: 14, Issue:5

    Topics: Clinical Trials as Topic; Dopamine Agonists; Forecasting; Levodopa; Movement Disorders; Polypharmacy; Receptors, Dopamine D2; Selegiline

1999
'On-off' phenomenon: description, incidence and management.
    European neurology, 1987, Volume: 27 Suppl 1

    Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline

1987

Trials

5 trial(s) available for selegiline and Movement Disorders

ArticleYear
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Movement Disorders; Parkinson Disease; Selegiline; Severity of Illness Index

2004
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
    Clinical neuropharmacology, 1995, Volume: 18, Issue:4

    Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone

1995
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1997, Volume: 63, Issue:2

    Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline

1997
Experiences with L-deprenyl in Parkinsonism.
    Journal of neural transmission, 1978, Volume: 43, Issue:3-4

    Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1978
R-(-)-deprenyl in the treatment of end-of-dose akinesia.
    Journal of neural transmission. Supplementum, 1987, Volume: 25

    Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1987

Other Studies

8 other study(ies) available for selegiline and Movement Disorders

ArticleYear
[Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
    Rinsho shinkeigaku = Clinical neurology, 2015, Volume: 55, Issue:3

    Topics: Aged; Benzothiazoles; Delayed-Action Preparations; Drug Substitution; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pramipexole; Selegiline

2015
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
    Modern problems of pharmacopsychiatry, 1983, Volume: 19

    Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1983
MAO-A and -B inhibitors selectively alter Xenopus mucus-induced behaviors of snakes.
    Pharmacology, biochemistry, and behavior, 1993, Volume: 44, Issue:2

    Topics: Analysis of Variance; Animals; Behavior, Animal; Clorgyline; Disease Models, Animal; Movement Disorders; Mucus; Selegiline; Snakes; Xenopus laevis

1993
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
    Clinical and experimental neurology, 1979, Volume: 16

    Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1979
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
    Journal of neural transmission, 1978, Volume: 43, Issue:3-4

    Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid

1978
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
    Journal of neural transmission. Supplementum, 1986, Volume: 22

    Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1986
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
    Journal of neural transmission. Supplementum, 1986, Volume: 22

    Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1986
Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine.
    Journal of neural transmission, 1988, Volume: 71, Issue:3

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Catecholamines; Caudate Nucleus; Dose-Response Relationship, Drug; Drug Interactions; Female; Injections, Intraventricular; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Nomifensine; Phenethylamines; Piperidines; Pyridinium Compounds; Selegiline; Serotonin

1988